6-O-angeloylplenolin inhibits anti-IgE-stimulated human mast cell activation via suppressing calcium influx and ERK phosphorylation

Document Type : Original Article


1 Shenzhen University Health Science Center, Shenzhen, China

2 Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

3 GI Division, Shenzhen University General Hospital, Shenzhen, China

4 School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China



Objective(s): Mast cells are important immune cells that primarily localize in the interface between the host and external environment, and protect us from pathogen infection. However, they are also involved in the pathology of allergic diseases such as asthma and atopic dermatitis. A novel S phase kinase-associated protein 1 (SKP1) inhibitor 6-O-angeloylplenolin (6-OAP), was studied with its potential ability to alleviate the anti-IgE-induced inflammatory responses of primary human cultured mast cells (HCMCs) and LAD2 cell line. 
Materials and Methods: We isolated the HCMCs from the buffy coat of voluntary blood donors. The effects of 6-OAP on mast cell activation were evaluated by measuring degranulation, cytokine release, migration, calcium influx, and ERK phosphorylation using spectro-fluorescence assay, multiplex cytometric bead assay/ELISA, migration assay, Fluo-4 calcium flux assay, and western blot, respectively. 
Results: It was found that 6-OAP exerted anti-inflammatory effects on human mast cells by dose-dependently suppressing the anti-IgE-mediated degranulation and release of cytokines such as proinflammatory cytokines (IL-8 and TNF-α), growth factors (GM-CSF, VEGF, and FGF), and chemokines (CCL2 and CCL3) in HCMC and LAD2 cells. It also suppressed the migration of immature HCMCs induced by CXCL12. Moreover, the process of calcium influx and ERK phosphorylation in activated HCMC cells were inhibited by 6-OAP administration. 
Conclusion: Our results showed that 6-OAP inhibited anti-IgE-induced inflammatory responses of human mast cells via suppressing calcium influx and ERK phosphorylation.


1. Cheng X, Liu YQ, Wang GZ, Yang LN, Lu YZ, Li XC, et al. Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor. Oncotarget 2017; 8:2681-2693.
2. Cardozo T, Pagano M. The SCF ubiquitin ligase: Insights into a molecular machine. Nat Rev Mol Cell Biol 2004; 5:739-751.
3. Wu Y, Kang J, Zhang L, Liang Z, Tang X, Yan Y, et al. Ubiquitination regulation of inflammatory responses through NF-κB pathway. Am J Transl Res 2018; 10:881-891.
4. Zemirli N, Pourcelot M, Dogan N, Vazquez A, Arnoult D. The E3 ubiquitin ligase RNF121 is a positive regulator of NF-κB activation. Cell Commun Signal 2014; 12:1-7.
5. Etzioni A, Ciechanover A, Pikarsky E. Immune defects caused by mutations in the ubiquitin system. J Allergy Clin Immunol 2017; 139:743-753.
6. Arthur G, Bradding P. New developments in mast cell biology: Clinical Implications. Chest 2016; 150:680-693.
7. Elieh Ali Komi D, Wohrl S, Bielory L. Mast cell biology at molecular level: a comprehensive review. Clin Rev Allergy Immunol 2020; 58:342-365.
8. Kyo S, Sada K, Qu X, Maeno K, Miah SM, Kawauchi-Kamata K, et al. Negative regulation of Lyn protein-tyrosine kinase by c-Cbl ubiquitin-protein ligase in Fc epsilon RI-mediated mast cell activation. Genes Cells 2003; 8:825-836.
9. Shmuel-Galia L, Humphries F, Lei X, Ceglia S, Fitzgerald KA. Dysbiosis exacerbates colitis by promoting ubiquitination and accumulation of the innate immune adaptor STING in myeloid cells. Immunity 2021; 54.
10. Ding LF, Liu Y, Liang HX, Liu DP, Zhou GB, Cheng YX. Two new terpene glucosides and antitumor agents from Centipeda minima. J Asian Nat Prod Res 2009; 11:732-736.
11. Tam IYS, Ng CW, Tam SY, Lau HYA. Novel six-week protocol for generating functional human connective tissue-type (MCTC) mast cells from buffy coats. Inflamm Res 2017; 66:25-37.
12. Kwon E, Li X, Deng Y, Chang HW, Kim DY. AMPK is down-regulated by the CRL4A-CRBN axis through the polyubiquitination of AMPKalpha isoforms. FASEB J 2019; 33:6539-6550.
13. Bambouskova M, Polakovicova I, Halova I, Goel G, Draberova L, Bugajev V, et al. New regulatory roles of galectin-3 in high-affinity ige receptor signaling. Mol Cell Biol 2016; 36:1366-1382.
14. Liu YQ, Wang XL, Cheng X, Lu YZ, Wang GZ, Li XC, et al. Skp1 in lung cancer: Clinical significance and therapeutic efficacy of its small molecule inhibitors. Oncotarget 2015; 6:34953-34967.
15. Cheng X, Liu YQ, Wang GZ, Yang LN, Lu YZ, Li XC, et al. Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor. Oncotarget 2017; 8:2681.
16. Tseng PC, Kuo CF, Cheng MH, Wan SW, Lin CF, Chang CP, et al. HECT E3 ubiquitin ligase-regulated txnip degradation facilitates tlr2-mediated inflammation during group a streptococcal infection. Front Immunol 2019; 10:2147.
17. Uematsu A, Kido K, Takahashi H, Takahashi C, Yanagihara Y, Saeki N, et al. The E3 ubiquitin ligase MIB2 enhances inflammation by degrading the deubiquitinating enzyme CYLD. J Biol Chem 2019; 294:14135-14148.
18. Gilfillan AM, Peavy RD, Metcalfe DD. Amplification mechanisms for the enhancement of antigen-mediated mast cell activation. Immunol Res 2009; 43:15-24.
19. Pastwinska J, Agier J, Dastych J, Brzezinska-Blaszczyk E. Mast cells as the strength of the inflammatory process. Pol J Pathol 2017; 68:187-196.
20. van Ree R, Hummelshøj L, Plantinga M, Poulsen LK, Swindle E. Allergic sensitization: Host-immune factors. Clin Transl Allergy 2014; 4:12.
21. Tanifuji S, Aizu-Yokota E, Funakoshi-Tago M, Sonoda Y, Inoue H, Kasahara T. Licochalcones suppress degranulation by decreasing the intracellular Ca2+ level and tyrosine phosphorylation of ERK in RBL-2H3 cells. Int Immunopharmacol 2010; 10:769-776.
22. Goru SK, Pandey A, Gaikwad AB. E3 ubiquitin ligases as novel targets for inflammatory diseases. Pharmacol Res 2016; 106:1-9.